Table 1 Baseline characteristics and demographics of CATIE study participants by PANSS Item G12 insight rating
Characteristic | All Patients N = 1431 | PANSS Insight Item Rating 1 to 4 (Absent to Moderate) n = 1293 (90%) | PANSS Insight Item Rating 5 to 7 (Moderate-Severe to Extreme) n = 138 (10%) | P value* |
|---|---|---|---|---|
Treatment for phase 1/1A, n (%a) | 0.7710 | |||
Olanzapine | 330 (23.1) | 304 (92.1) | 26 (7.9) | |
Perphenazine | 256 (17.9) | 228 (89.1) | 28 (10.9) | |
Quetiapine | 330 (23.1) | 298 (90.3) | 32 (9.7) | |
Risperidone | 333 (23.3) | 299 (89.8) | 34 (10.2) | |
Ziprasidone | 182 (12.7) | 164 (90.1) | 18 (9.9) | |
Age, y, mean (SD) | 40.6 (11.1) | 40.7 (11.0) | 39.6 (12.1) | 0.2815 |
Age group, n (%a) | 0.0998 | |||
18–35 years | 449 (31.4) | 395 (88.0) | 54 (12.0) | |
36–45 years | 476 (33.3) | 438 (92.0) | 38 (8.0) | |
46+ years | 506 (35.4) | 460 (90.9) | 46 (9.1) | |
Sex, n (%a) | 0.0820 | |||
Male | 1063 (74.3) | 952 (89.6) | 111 (10.4) | |
Female | 368 (25.7) | 341 (92.7) | 27 (7.3) | |
Race, n (%a) | 0.2376 | |||
White | 875 (61.1) | 789 (90.2) | 86 (9.8) | |
Black | 506 (35.4) | 462 (91.3) | 44 (8.7) | |
Other | 50 (3.5) | 42 (84.0) | 8 (16.0) | |
Marital status, n (%a) | 0.0478 | |||
Married | 166 (11.6) | 156 (94.0) | 10 (6.0) | |
Previously married | 414 (28.9) | 381 (92.0) | 33 (8.0) | |
Never married | 851 (59.5) | 756 (88.8) | 95 (11.2) | |
Patient education, n (%a) | 0.2445 | |||
< 12 years | 365 (25.5) | 336 (92.1) | 29 (7.9) | |
12 years | 506 (35.4) | 449 (88.7) | 57 (11.3) | |
> 12 years | 560 (39.1) | 508 (90.7) | 52 (9.3) | |
Employed, n (%a) | 0.3161 | |||
No | 1213 (84.8) | 1092 (90.0) | 121 (10.0) | |
Yes | 218 (15.2) | 201 (92.2) | 17 (7.8) | |
Lives alone, n (%a) | 0.2536 | |||
No | 1084 (75.8) | 974 (89.9) | 110 (10.1) | |
Yes | 347 (24.2) | 319 (91.9) | 28 (8.1) |